Award
National Cancer Institute 11174404
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
Recipient
UNIVERSITY OF TX MD ANDERSON CAN CTR
Award Amount
$636,578.00
Ceiling
$636,578.00
Awarded
August 11, 2025
Identifier
11174404
This award funds a multi-year research project at the University of Texas MD Anderson Cancer Center to study the effects of arginine depletion combined with chemotherapy in aggressive prostate cancers, focusing on safety, efficacy, and immune response.
Description
The project involves clinical trials and preclinical studies focusing on prostate cancer. It aims to evaluate the safety, efficacy, and immune effects of combining ADI-PEG20 with chemotherapy in aggressive prostate cancer. The project includes multiple aims involving dose escalation, biomarker analysis, and immune profiling, emphasizing the importance of arginine metabolism and immune microenvironment in prostate cancer treatment. It is part of a multi-year effort with a focus on translational research and clinical application.